Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs
- J. L. Tomlin, BSc, BVetMed, MRCVS1,
- C. Sturgeon, BVetMed, MRCVS1,
- M. J. Pead, BVetMed, PhD, MRCVS1 and
- P. Muir, BVSc, MVetClinStud, PhD, MACVSc, MRCVS, DipACVS, DipECVS1,1
The bisphosphonate drug alendronate was used to suppress bone remodelling and tumour osteolysis as a palliative treatment for two dogs with osteosarcoma, one of the tibia and one of the maxilla. A spiral fracture associated with the tibial tumour healed after it was stabilised with an external skeletal fixator. Both dogs remained comfortable and survived for 12 and 10 months respectively after diagnosis, despite the fact that neither primary tumour was resected.
- British Veterinary Association. All rights reserved.